Alnylam Pharmaceuticals (ALNY) Competitors $240.01 +2.24 (+0.94%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. REGN, BIIB, UTHR, INCY, BMRN, EXEL, NBIX, EXAS, HALO, and MDGLShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Regeneron Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Regeneron Pharmaceuticals (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Which has better earnings and valuation, REGN or ALNY? Regeneron Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B4.40$4.41B$38.2814.92Alnylam Pharmaceuticals$2.25B13.89-$278.16M-$2.17-110.60 Do analysts recommend REGN or ALNY? Regeneron Pharmaceuticals presently has a consensus target price of $964.88, indicating a potential upside of 68.96%. Alnylam Pharmaceuticals has a consensus target price of $315.58, indicating a potential upside of 31.49%. Given Regeneron Pharmaceuticals' higher possible upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.77Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77 Which has more risk & volatility, REGN or ALNY? Regeneron Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Is REGN or ALNY more profitable? Regeneron Pharmaceuticals has a net margin of 31.07% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.07% 16.32% 12.76% Alnylam Pharmaceuticals -12.37%N/A -6.83% Do institutionals & insiders have more ownership in REGN or ALNY? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor REGN or ALNY? In the previous week, Regeneron Pharmaceuticals had 15 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 45 mentions for Regeneron Pharmaceuticals and 30 mentions for Alnylam Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 1.14 beat Alnylam Pharmaceuticals' score of 0.80 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 31 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 15 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer REGN or ALNY? Regeneron Pharmaceuticals received 387 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRegeneron PharmaceuticalsOutperform Votes155066.95% Underperform Votes76533.05% Alnylam PharmaceuticalsOutperform Votes116376.31% Underperform Votes36123.69% SummaryRegeneron Pharmaceuticals beats Alnylam Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.22B$6.37B$5.35B$7.58BDividend YieldN/A3.20%5.11%4.33%P/E Ratio-110.606.8021.6517.79Price / Sales13.89228.59375.8994.27Price / CashN/A65.6738.1534.64Price / Book461.565.886.443.99Net Income-$278.16M$141.32M$3.20B$247.24M7 Day Performance3.03%5.19%6.67%5.84%1 Month Performance-0.72%-12.91%-6.27%-5.78%1 Year Performance61.62%-14.85%8.56%-1.99% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.5026 of 5 stars$240.01+0.9%$315.58+31.5%+61.6%$31.22B$2.25B-110.602,000REGNRegeneron Pharmaceuticals4.8477 of 5 stars$572.78-0.1%$966.88+68.8%-36.9%$62.62B$14.20B14.9611,900Analyst ForecastPositive NewsHigh Trading VolumeBIIBBiogen4.6983 of 5 stars$119.19-3.1%$213.33+79.0%-39.8%$17.45B$9.68B10.658,720UTHRUnited Therapeutics4.9041 of 5 stars$291.72-0.3%$388.25+33.1%+22.2%$13.10B$2.88B12.81980Positive NewsINCYIncyte4.798 of 5 stars$60.29-0.5%$74.88+24.2%+10.0%$11.67B$4.24B223.302,320BMRNBioMarin Pharmaceutical4.8659 of 5 stars$59.16-1.8%$94.00+58.9%-35.3%$11.29B$2.85B26.893,401Gap UpHigh Trading VolumeEXELExelixis4.256 of 5 stars$34.84+0.8%$37.59+7.9%+56.7%$9.75B$2.17B19.681,220Positive NewsGap DownNBIXNeurocrine Biosciences4.8385 of 5 stars$93.25-2.5%$163.52+75.4%-29.5%$9.30B$2.36B28.341,200Analyst UpgradeNews CoveragePositive NewsGap UpHigh Trading VolumeEXASExact Sciences4.2289 of 5 stars$43.83+3.0%$70.26+60.3%-38.0%$8.14B$2.76B-7.876,400Analyst ForecastPositive NewsGap DownHigh Trading VolumeHALOHalozyme Therapeutics4.3934 of 5 stars$59.35-0.7%$62.78+5.8%+59.0%$7.33B$1.02B17.30390Positive NewsMDGLMadrigal Pharmaceuticals4.0512 of 5 stars$310.52-1.2%$378.44+21.9%+36.2%$6.86B$180.13M-12.3890News CoveragePositive NewsGap Up Remove Ads Related Companies and Tools Related Companies Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Neurocrine Biosciences Alternatives Exact Sciences Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
